Imaging scan to detect kidney cancer in complex kidney cysts before surgery
Tests a PET scan using 68Ga-NYM096 to find kidney cancer in cysts before surgery.
Plain-language title generated from the registry record
Registry title: 68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a complex kidney cyst who are scheduled for surgery. It tests a PET/CT scan to find clear cell kidney cancer before the operation.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A complex kidney cyst (Bosniak category II or higher) that is planned for surgical removal. Expected survival of at least 3 months and ECOG 2 or lower.
- Earlier treatment
- People who took a VEGF TKI drug (such as sunitinib, sorafenib, cabozantinib, pazopanib or lenvatinib) need a break of 1 week before the scan.
Main reasons for not taking part
- VEGF TKI treatment less than 1 week before the scan
- Another medical condition that rules out surgery
- Pregnancy or breastfeeding
- Severe claustrophobia
Read by machine on 12 November 2026.
Where in China
- Peking Union Medical CollegeBeijing, ChinaContact: Li HuoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT06949215
- Record updated
- 26 May 2026
- Original description
This is a prospective, single-center, single-arm, diagnostic phase 2 study aimed at evaluating the sensitivity and specificity of 68Ga-NYM096 PET/CT in detecting clear cell renal cell carcinoma (ccRCC) in patients with complex renal cysts who are scheduled for surgical resection. The study will use histopathological diagnosis as the reference standard to assess the diagnostic accuracy of 68Ga-NYM096 PET/CT in identifying ccRCC within operable complex renal cystic lesion. The findings will provide critical insights into the performance of 68Ga-NYM096 PET/CT as a non-invasive imaging tool for the preoperative detection of ccRCC in this patient population.Read full original descriptionShow less
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Complex Cystic Renal Leision
This is a prospective, single-center, single-arm, diagnostic phase 2 study aimed at evaluating the sensitivity and specificity of 68Ga-NYM096 PET/CT in detecting clear cell renal cell carcinoma (ccRCC) in patients with complex renal cysts who are scheduled for surgical resection. The study will use histopathological diagnosis as the reference standard to assess the diagnostic accuracy of 68Ga-NYM096 PET/CT in identifying ccRCC within operable complex renal cystic lesion. The findings will provide critical insights into the performance of 68Ga-NYM096 PET/CT as a non-invasive imaging tool for the preoperative detection of ccRCC in this patient population.
Inclusion: Age ≥ 18 y; Presence of complex renal cyst (Bosniak category II or higher); Scheduled for surgical resection of renal mass (partial or total nephrectomy, open, laparoscopic, or robot-assisted technique); Expected survival of at least 3 months; ECOG ≤ 2; Written informed consent provided for participation in the trial; In the opinion of investigator, willing and able to comply with required study procedures.
Exclusion: On VEGF TKI treatment less than 1 week before 68Ga-NYM096 PET/CT. TKI is known to affect girentuximab binding in patients with ccRCC and is expected to have the same effect on 68Ga-NYM096. If patients were on VEGF TKI treatment, such as sunitinib, sorafenib, cabozantinib, pazopanib, or lenvatinib, a washout of one week before 68Ga-NYM096 PET/CT is required; Intercurrent medical condition that renders the patient ineligible for surgery; Pregnancy or breastfeeding; Severe claustrophobia.